Cellular responses to halofuginone reveal a vulnerability of the GCN2 branch of the integrated stress response

Halofuginone (HF) is a phase 2 clinical compound that inhibits the glutamyl‐prolyl‐tRNA synthetase (EPRS) thereby inducing the integrated stress response (ISR). Here, we report that halofuginone indeed triggers the predicted canonical ISR adaptations, consisting of attenuation of protein synthesis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitera, Aleksandra P, Szaruga, Maria, Peak‐Chew, Sew‐Yeu, Wingett, Steven W, Bertolotti, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156968/
https://www.ncbi.nlm.nih.gov/pubmed/35466425
http://dx.doi.org/10.15252/embj.2021109985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156968/
https://www.ncbi.nlm.nih.gov/pubmed/35466425
http://dx.doi.org/10.15252/embj.2021109985

Ejemplares similares